@CARTTherapy profile picture
Chimeric Antigen Receptor T-Cell (CAR-T) & Gene Rx @CARTTherapy

Cellular & Gene Therapy Program @ KFSHRC KSA #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy

Joined December 2019
  • Tweets 4,415
  • Following 77
  • Followers 4,547
1,206 Photos and videos
Survodutide Once Weekly for the Treatment of Adults with Obesity | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…

Survodutide Once Weekly for the Treatment of Adults with Obesity | NEJM

Although medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity have transformed the management of obesity and shown substantial cardiometabolic benefits, unmet needs remain. Su...

nejm.org
1
257
Guanylyl Cyclase 2C–Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…

Guanylyl Cyclase 2C–Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic...

PURPOSEThe clinical efficacies of third- or later-line therapies for metastatic colorectal cancer (CRC) are extremely limited. The purpose of this study was to evaluate the safety and efficacy of a...

ascopubs.org
3
304
Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…

Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy | NEJM

HLA sensitization poses a major challenge to kidney transplantation for patients with end-stage kidney disease, especially for highly sensitized candidates. Attempts at antibody elimination (desens...

nejm.org
1
7
1,000
Chimeric Antigen Receptor T-Cell (CAR-T) & Gene Rx retweeted
NEJM
@NEJM
Jun 8
Original Article: All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia (ASCERTAIN-V trial) nej.md/4fpoGzl #Hematology
This image contains a multi-section figure related to dose adjustments for a study. Section A is a flowchart titled "Recommended Approach to Dose Adjustments for Phase 2b." Section B is a graph showing the percentage of patients who received venetoclax for 28 days across cycles 1 to 4 in Phase 1, Phase 2a, and Phase 2b. Section C presents a graph displaying the percentage of patients who received DEC-C for 5 days over the same cycles and phases.

ALT This image contains a multi-section figure related to dose adjustments for a study. Section A is a flowchart titled "Recommended Approach to Dose Adjustments for Phase 2b." Section B is a graph showing the percentage of patients who received venetoclax for 28 days across cycles 1 to 4 in Phase 1, Phase 2a, and Phase 2b. Section C presents a graph displaying the percentage of patients who received DEC-C for 5 days over the same cycles and phases.

Survival curve graph depicting the percentage of patients surviving over 42 months across three study phases: Phase 1, Phase 2a, and Phase 2b. Phases 2a and 2b have separate lines. Median overall survival is noted, with Phase 1 at 6.8 months, Phase 2a at 14.5 months, and Phase 2b at 17.5 months. A table below shows the number of patients at risk for each phase.

ALT Survival curve graph depicting the percentage of patients surviving over 42 months across three study phases: Phase 1, Phase 2a, and Phase 2b. Phases 2a and 2b have separate lines. Median overall survival is noted, with Phase 1 at 6.8 months, Phase 2a at 14.5 months, and Phase 2b at 17.5 months. A table below shows the number of patients at risk for each phase.

1
11
62
15,809
ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia ashpublications.org/blood/ar…

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia

FLT3-ITD measurable residual disease (MRD) testing for patients in remission from acute myeloid leukemia (AML) is now recommended by the recently updated c

ashpublications.org
5
926
Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL ashpublications.org/blood/ar… In 3L treatment of patients with R/R LBCL, liso-cel achieved 5-year overall survival of 38% and disease-specific survival of 52%. •

Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL

Key Points. In 3L treatment of patients with R/R LBCL, liso-cel achieved 5-year overall survival of 38% and disease-specific survival of 52%.The durable l

ashpublications.org
2
3
507
Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial - The Lancet Haematology thelancet.com/journals/lanha…
1
3
1,151
Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease | Journal of Clinical Oncology ascopubs.org/doi/pdf/10.1200…
4
531
From Molecular Complexity to Personalized Care in Chronic Myelomonocytic Leukemia | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…

From Molecular Complexity to Personalized Care in Chronic Myelomonocytic Leukemia

ascopubs.org
4
13
1,516
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy | Journal of Clinical Oncology ascopubs.org/doi/pdf/10.1200…
8
697
Trends in survival outcomes after allogeneic transplantation for MDS and MDS/MPN in a real-world experience: A 25-year nationwide study onlinelibrary.wiley.com/doi/…

Trends in survival outcomes after allogeneic transplantation for MDS and MDS/MPN in a real‐world...

Post-transplant survivals improved in de novo myelodysplastic syndrome, chronic myelomonocytic leukaemia and atypical chronic myeloid leukaemia, but not myelodysplastic/myeloproliferative neoplasm-...

onlinelibrary.wiley.com
3
12
1,064
Treosulfan–fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study onlinelibrary.wiley.com/shar…
1
2
473
Chimeric Antigen Receptor T-Cell (CAR-T) & Gene Rx retweeted
Mostafa Faisal@MostafaFaisal14
Apr 14
Asciminib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Case Series and Review of Emerging Evidence | MDPI share.google/LO0wVH5Og8aif04…

Asciminib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Case Series and...

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph ALL) remains a high-risk entity despite advances in tyrosine kinase inhibitors (TKIs), immunotherapy, and cellular therapies....

mdpi.com
2
5
17
2,324
Concomitant or sequential lower intensity triplet therapy in AML - The Lancet Haematology thelancet.com/journals/lanha…

Concomitant or sequential lower intensity triplet therapy in AML

Jayastu Senapati and Naval G Daver

thelancet.com
6
637
Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet Haematology thelancet.com/journals/lanha…

Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis...

To the best of our knowledge, this trial provides the first clinical evidence and proof-of-concept for bradykinin B2 receptor antagonism as a therapeutic approach for the prevention of hereditary...

thelancet.com
307
Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies - The Lancet Haematology thelancet.com/journals/lanha…

Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignan...

The development of novel T-cell redirecting immune therapies—including immune checkpoint inhibitors, bispecific antibodies, chimeric antigen receptor T cells, and virus-specific T cells—represents a...

thelancet.com
2
5
643
Randomized trial of GvHD Prophylaxis in Haploidentical PBSC Transplantation: ATG, PTCy, and Low-Dose Combination Therapy ashpublications.org/blood/ar…

Randomized trial of GvHD Prophylaxis in Haploidentical PBSC Transplantation: ATG, PTCy, and...

Key Points. Low-dose ATG/PTCy, standard-dose ATG, and PTCy regimens showed similar grade II–IV acute GvHD and 1-year GRFS in haplo-PBSCT.ATG/PTCy significa

ashpublications.org
7
14
1,346
Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia ashpublications.org/blood/ar…

Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with...

Key Points. Among patients treated with intravenous iron, ferric carboxymaltose was associated with a higher fracture risk than ferric derisomaltoseFerric

ashpublications.org
6
544
Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models ashpublications.org/blood/ar…

Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models

Key Points. Ziftomenib shows pronounced preclinical activity in the menin-KMT2A-dependent leukemia models, including patient-derived xenograftsZiftomenib d

ashpublications.org
2
437
Tocilizumab as stabilizing frontline treatment in suspected KSHV inflammatory cytokine syndrome ashpublications.org/bloodadv…

Tocilizumab as stabilizing frontline treatment in suspected KSHV inflammatory cytokine syndrome

Kaposi sarcoma herpesvirus (KSHV) is associated with the endothelial cell cancer, Kaposi sarcoma (KS), and the B-cell lymphoproliferative disorders, KSHV-a

ashpublications.org
2
11
1,156
Load more